Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final
approval by the United States Food & Drug Administration (U.S. FDA) for its Lacosamide Tablets USP,50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat Tablets, 50 mg, 100 mg, 150 mg
and 200 mg of UCB, Inc. The company plans to launch the product immediately.
According to IQVIA™ sales data for the 12 month period ending January 2022, the Vimpat Tablets, 50 mg, 100 mg, 150 mg and 200 mg market achieved annual sales of approximately $1.7 billion
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
